NewsBenzingaEvercore ISI Group维持Ultragenyx Pharmaceutical的股票评级为“符合市场预期”，将目标股价上调至18美元 Evercore ISI Group维持Ultragenyx Pharmaceutical的股票评级为“符合市场预期”，将目标股价上调至18美元 Benzinga 2026.09.21 16:30 (GMT+0) Open on Benzinga Other news Wells Fargo Maintains Equal-Weight on Sonoco Products, Lowers Price Target to $53 Piper Sandler Maintains Neutral on WaFd, Lowers Price Target to $31 VinFast Says Real Estate Could Cover Its EV Cash Burn Wells Fargo Maintains Overweight on Silgan Hldgs, Lowers Price Target to $52 Piper Sandler Maintains Neutral on First Finl Bankshares, Lowers Price Target to $33 $1000 Invested In Extra Space Storage 20 Years Ago Would Be Worth This Much Today
